Literature DB >> 1491407

Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy.

M Dahl1, A Chalmers, J Wade, D Calverley, B Munt.   

Abstract

Pulmonary hypertension is the most frequent cause of death in patients with mixed connective tissue disease. The pulmonary hypertension is progressive and difficult to treat effectively. These patients experience considerable morbidity secondary to diminished cardiac function. We describe a case in which sequential administration of cyclophosphamide and cyclosporine A favorably altered the clinical and hemodynamic course of this serious complication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1491407

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Improvement of severe pulmonary hypertension in a patient with SLE.

Authors:  M Karmochkine; B Wechsler; P Godeau; F Brenot; J L Jagot; G Simonneau
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.

Authors:  Eileen M Bauer; Richard Shapiro; Han Zheng; Ferhaan Ahmad; David Ishizawar; Suzy A Comhair; Serpil C Erzurum; Timothy R Billiar; Philip M Bauer
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354

5.  Pulmonary vascular reactivity in severe pulmonary hypertension associated with mixed connective tissue disease.

Authors:  P Jolliet; J B Thorens; J C Chevrolet
Journal:  Thorax       Date:  1995-01       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.